Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.

The research article details the creation of a trivalent single-chain variable fragment antibody (scFv50AD1-Fd) engineered to counteract rabies virus. The recombinant antibody, generated in bacteria and purified, has shown to possess significantly improved potency in neutralizing the rabies virus compared to current human and equine rabies immunoglobins used for passive immunization.

Creation and testing of the scFv50AD1-Fd antibody

• The monoclonal antibody scFv50AD1-Fd was engineered using genetic fusion techniques to create a trivalent structure that targets the rabies virus glycoprotein, a surface protein on the virus crucial for its infection capabilities. This was accomplished by utilizing the foldon domain of the T4 bacteriophage, a protein known for encouraging trimer formation.
• The trimeric antibody was then produced in a bacterial periplasmic space and purified via affinity chromatography.
• The researchers examined the trivalent antibody’s integrity and stability using various analytic methods including polyacrylamide gradient-gel electrophoresis and size-exclusion chromatography. The antibody was also exposed to human sera to validate its stability within a biological context.

Evaluating the trivalent scFv50AD1-Fd antibody

• The trivalent scFv50AD1-Fd’s binding to the rabies virus glycoprotein was confirmed using direct and competitive-ELISA tests.
• It was found that the trivalent scFv50AD1-Fd antibody had an affinity constant 75 times greater than its monovalent counterpart, implying significantly improved binding to the target glycoprotein.
• The neutralizing potency of the engineered antibody was then tested using both in vitro and in vivo assays. The result showed an increase in neutralizing activity up to 75 times greater than both the monovalent format and the current World Health Organization standard serum.

Implications of the study

• The significantly improved potency of the engineered trivalent scFv50AD1-Fd antibody not only offers a potential advancement in rabies protection but also illustrates the potential of antibody engineering for disease immunotherapy.
• These findings may guide future strategies in designing the next generation of anti-rabies antibodies and, potentially, antibodies against other diseases.